Cargando…
Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab
BACKGROUND: Pembrolizumab is an anti–programmed death 1 (PD-1) receptor monoclonal antibody that has shown activity as second line treatment for metastatic head and neck squamous cell carcinoma (HNSCC). Immune-related adverse events are now well described complications of PD-1 inhibitors and most or...
Autores principales: | Acero Brand, Fanny Zulay, Suter, Nicolas, Adam, Jean-Philippe, Faulques, Bernard, Maietta, Antonio, Soulières, Denis, Blais, Normand |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857140/ https://www.ncbi.nlm.nih.gov/pubmed/29548299 http://dx.doi.org/10.1186/s40425-018-0332-z |
Ejemplares similares
-
Plasma cell mucositis of the larynx
por: Smith, Jonathan G. F., et al.
Publicado: (2018) -
Dramatic response of refractory metastatic squamous cell carcinoma of the
skin with cetuximab/pembrolizumab
por: Hober, Candice, et al.
Publicado: (2021) -
Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world
por: Zhang, Pei, et al.
Publicado: (2022) -
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
por: Harrington, Kevin J., et al.
Publicado: (2023) -
Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design
por: Zheng, Yuyan, et al.
Publicado: (2021)